Interleukin-1 receptor associated kinase 2 is a functional downstream regulator of complement factor D that controls mitochondrial fitness in diabetic cardiomyopathy

Diabetic cardiomyopathy is a disorder of the cardiac muscle that affects patients with diabetes. The exact mechanisms underlying diabetic cardiomyopathy are mostly unknown, but several factors have been implicated in the pathogenesis of the disease and its progression towards heart failure, including endothelial dysfunction, autonomic neuropathy, metabolic alterations, oxidative stress, and alterations in ion homeostasis, especially calcium transients [1]. In Military Medical Research, Jiang et al. [2] sought to determine the functional role of complement factor D (Adipsin) in the pathophysiology of diabetic cardiomyopathy.

Complement factor D is a protein secreted into the bloodstream mainly by adipocytes. It is also known as Adipsin, C3 pro-activator convertase, or properdin factor D esterase. The protein is a member of the trypsin family of serine proteases and has a high level of expression in fat, implying a functional role for adipose tissue in immune system biology. Complement factor D is involved in the alternative pathway of the complement system where it cleaves factor B1 [3].

HFD feeding is usually used to obtain animal models of type 2 diabetes mellitus (T2DM), because chronic HFD feeding is capable of inducing hyperglycemia, insulin resistance and glucose intolerance, and similar manifestations of T2DM. Animal models that can nicely recapitulate human T2DM are crucial to examine the pathogenesis and intervention strategies for diabetes and diabetic complications [4, 5].

In their experimental setting, Jiang et al. [2] observed that HFD feeding for 6 months induced a pronounced hyperglycemia as well as diastolic and systolic cardiac dysfunction. They detected reduced serum levels of complement factor D starting at the 2nd month of HFD feeding, which is consistent with previous observations showing that circulating levels of complement factor D decreased in obese patients [6]; such reduction may be due to high activity or resistance, albeit the exact causes are not fully known.

Mass spectrometry (MS) analysis was used to screen the potential proteins that directly interact with complement factor D in cardiomyocytes [2]. The top 5 proteins with high MS scores were interleukin-1 receptor-associated kinase like 2 (Irak2), hemoglobin subunit beta-1 (Hbb-b1), hemoglobin subunit alpha (Hb-α), myosin regulatory light chain 2 (Myl2), and myosin light chain 3 (Myl3). After reviewing the functions of these proteins, Jiang et al. [2] noticed that Irak2 is known to participate in the regulation of cardiomyocyte apoptosis in models of diabetic cardiomyopathy. Additionally, mitochondrial translocation of Irak2 regulates oxidative metabolism in adipocytes [7].

Irak2 is one of the two putative serine/threonine kinases that are associated with the IL-1 receptor upon stimulation. It is involved in the IL-1 receptor/Toll-like receptor (TLR) signaling cascade and is known to act as an adaptor in the TLR-MyD88-TNF receptor associated factor 6 (TRAF6) complex, enabling the downstream activation of NF-κB and thereby regulating inflammation [7]. Irak2 has been shown to translocate in the mitochondrion where it localizes to the inner mitochondrial membrane [7]. At this level, it interacts with prohibitin (PHB), causing PHB to recruit optic atrophy protein 1 (Opa1, also known as dynamin-like 120 kD protein, a fundamental orchestrator of mitochondrial fusion [5]) from the cristae junctions, and suppresses respiratory super-complex formation, ultimately triggering a destabilization of mitochondrial integrity [7].

On these grounds, Jiang et al. [2] further evaluated the interaction between complement factor D and Irak2. Intriguingly, glutathione-S-transferase (GST)-pulldown technique, co-immunoprecipitation, and immunofluorescence co-localization studies established that Irak2 serves as a downstream regulator of complement factor D. Mechanistically, adipose tissue-specific overexpression of complement factor D significantly improved cardiac function and alleviated cardiac remodeling in diabetic cardiomyopathy, but these effects were not observed after Irak2 knockdown.

The compelling evidence provided in the work led by Jiang et al. [2] indicates that increased complement factor D inhibits Irak2 mitochondrial translocation in the diabetic myocardium, decreasing the interaction between Irak2 and PHB-Opa1, eventually reducing mitochondrial cristae damage and improving mitochondrial fitness (Fig. 1), thereby attenuating the impaired myocardial fatty acid metabolism detected in diabetic cardiomyopathy.

Fig. 1

In diabetic cardiomyopathy, interleukin-1 receptor associated kinase 2 (Irak2) translocates in the mitochondrion, where it triggers the recruitment of optic atrophy protein 1 (Opa1, also known as dynamin-like 120 kD protein) from the cristae junctions by prohibitin, destabilizing the organelle integrity and impairing its function. Complement factor D (Adipsin) inhibits the mitochondrial translocation of Irak2, eventually attenuating myocardial dysfunction

Full size image

A strength of the paper is that both immunocolloidal gold electron microscopy and immunoblot analyses confirmed that complement factor D inhibits mitochondrial translocation of Irak2 in diabetic cardiomyopathy, thus reducing the interaction between Irak2 and PHB-Opa1 on mitochondria and improving the structural integrity and function of mitochondria. Limitations include having performed the investigations exclusively in cardiomyocytes, without testing other cardiac cells, and in animal models, without verifying the effects in human cells.

The mice used in this study were C57BL/6J, which are a substrain that is known to carry a mutation in the nicotinamide nucleotide transhydrogenase (Nnt) gene, which may affect cellular metabolism. The Nnt gene is located on the murine chromosome 13 and encodes a mitochondrial protein involved in mitochondrial metabolism. C57BL/6J mice have a spontaneous in-frame 5-exon deletion in Nnt that removes exons 7–11, resulting in inappropriate glucose homeostasis in male C57BL/6J mice [8, 9]. C57BL/6J mice have a normal life span and actually have a robust weight gain and develop obesity and insulin resistance on a HFD. Instead, C57BL/6N lines do not have this mutation and should be preferred in studies investigating mitochondrial phenotypes, and diabetes-related features. Nevertheless, recent investigations suggest that the lack of functional Nnt contributes only moderately to the differences in glucose-stimulated insulin secretion and glucose tolerance between the two strains [10].

In summary, serum levels of complement factor D are reduced in HFD-fed mice, associated with hyperglycemia and cardiac dysfunction. Increasing complement factor D inhibits mitochondrial translocation of Irak2, alleviating mitochondrial damage and improving cardiac function in diabetic cardiomyopathy. Irak2 appears crucial in this context, influencing mitochondrial integrity and suggesting a potential therapeutic pathway for diabetic cardiomyopathy.

Not applicable.

HFD:

High fat diet

Irak2:

Interleukin-1 receptor-associated kinase like 2

Nnt:

Nicotinamide nucleotide transhydrogenase

PHB:

Prohibitin

T2DM:

Type 2 diabetes mellitus

TLR:

Toll-like receptor

TRAF6:

TNF receptor associated factor 6

1. Jankauskas SS, Kansakar U, Varzideh F, Wilson S, Mone P, Lombardi A, et al. Heart failure in diabetes. Metabolism. 2021;125:154910.

   Article CAS PubMed PubMed Central Google Scholar

2. Jiang MY, Man WR, Zhang XB, Zhang XH, Duan Y, Lin J, et al. Adipsin inhibits Irak2 mitochondrial translocation and improves fatty acid β-oxidation to alleviate diabetic cardiomyopathy. Mil Med Res. 2023;10(1):63.

   CAS PubMed PubMed Central Google Scholar

3. Barthelemy J, Bogard G, Wolowczuk I. Beyond energy balance regulation: the underestimated role of adipose tissues in host defense against pathogens. Front Immunol. 2023;14:1083191.

   Article CAS PubMed PubMed Central Google Scholar

4. Alex L, Tuleta I, Hanna A, Frangogiannis NG. Diabetes induces cardiac fibroblast activation, promoting a matrix-preserving nonmyofibroblast phenotype, without stimulating pericyte to fibroblast conversion. J Am Heart Assoc. 2023;12(6):e027463.

   Article CAS PubMed PubMed Central Google Scholar

5. de Rosa M, Gambardella J, Shu J, Santulli G. Dietary fat is a key determinant in balancing mitochondrial dynamics in heart failure: a novel mechanism underlying the obesity paradox. Cardiovasc Res. 2018;114(7):925–7.

   Article PubMed PubMed Central Google Scholar

6. Milek M, Moulla Y, Kern M, Stroh C, Dietrich A, Schon MR, et al. Adipsin serum concentrations and adipose tissue expression in people with obesity and type 2 diabetes. Int J Mol Sci. 2022;23(4):2222.

   Article CAS PubMed PubMed Central Google Scholar

7. Zhou H, Wang H, Yu M, Schugar RC, Qian W, Tang F, et al. IL-1 induces mitochondrial translocation of IRAK2 to suppress oxidative metabolism in adipocytes. Nat Immunol. 2020;21(10):1219–31.

   Article CAS PubMed PubMed Central Google Scholar

8. Freeman HC, Hugill A, Dear NT, Ashcroft FM, Cox RD. Deletion of nicotinamide nucleotide transhydrogenase: a new quantitive trait locus accounting for glucose intolerance in C57BL/6J mice. Diabetes. 2006;55(7):2153–6.

   Article CAS PubMed Google Scholar

9. Williams JL, Hall CL, Meimaridou E, Metherell LA. Loss of Nnt increases expression of oxidative phosphorylation complexes in C57BL/6J hearts. Int J Mol Sci. 2021;22(11):6101.

   Article CAS PubMed PubMed Central Google Scholar

10. Close AF, Chae H, Jonas JC. The lack of functional nicotinamide nucleotide transhydrogenase only moderately contributes to the impairment of glucose tolerance and glucose-stimulated insulin secretion in C57BL/6J vs C57BL/6N mice. Diabetologia. 2021;64(11):2550–61.

    Article CAS PubMed Google Scholar

Download references

Not applicable.

The Santulli’s Lab is currently supported in part by the National Institutes of Health (NIH): National Heart, Lung, and Blood Institute (NHLBI: R01-HL164772, R01-HL159062, R01-HL146691, T32-HL144456), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK: R01-DK123259, R01-DK033823), the National Center for Advancing Translational Sciences (NCATS: UL1-TR002556-06, UM1-TR004400) (to Gaetano Santulli), the Diabetes Action Research and Education Foundation (to Gaetano Santulli), and the Monique Weill-Caulier and Irma T. Hirschl Trusts (to Gaetano Santulli).

Authors and Affiliations

1. Department of Medicine, Fleischer Institute for Diabetes and Metabolism (FIDAM), Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Einstein Institute for Aging Research, Albert Einstein College of Medicine, New York, NY, 10461, USA

   Stanislovas S. Jankauskas, Urna Kansakar, Francesco Di Lorenzo, Angela Lombardi & Gaetano Santulli

2. Department of Molecular Pharmacology, Division of Cardiology, Wilf Family Cardiovascular Research Institute, Albert Einstein College of Medicine, New York, NY, 10461, USA

   Fahimeh Varzideh, Pasquale Mone & Gaetano Santulli

Authors

1. Stanislovas S. JankauskasView author publications

   You can also search for this author in PubMed Google Scholar

2. Fahimeh VarzidehView author publications

   You can also search for this author in PubMed Google Scholar

3. Pasquale MoneView author publications

   You can also search for this author in PubMed Google Scholar

4. Urna KansakarView author publications

   You can also search for this author in PubMed Google Scholar

5. Francesco Di LorenzoView author publications

   You can also search for this author in PubMed Google Scholar

6. Angela LombardiView author publications

   You can also search for this author in PubMed Google Scholar

7. Gaetano SantulliView author publications

   You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the preparation of the manuscript. All authors read and approved the final draft for publication.

Corresponding author

Correspondence to Gaetano Santulli.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

Cite this article

Jankauskas, S.S., Varzideh, F., Mone, P. et al. Interleukin-1 receptor associated kinase 2 is a functional downstream regulator of complement factor D that controls mitochondrial fitness in diabetic cardiomyopathy. Military Med Res 11, 1 (2024). https://doi.org/10.1186/s40779-023-00506-3

Download citation

• Received: 22 November 2023

• Accepted: 18 December 2023

• Published: 03 January 2024

• DOI: https://doi.org/10.1186/s40779-023-00506-3

Share this article

Anyone you share the following link with will be able to read this content:

Get shareable link

Sorry, a shareable link is not currently available for this article.

Copy to clipboard

Provided by the Springer Nature SharedIt content-sharing initiative

Keywords

• Adipsin
• Complement factor D
• Interleukin-1
• Interleukin-1 receptor-associated kinase like 2 (Irak2)
• Opa1
• Prohibitin (PHB)